Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Go back to Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 11.76 +0.58 (5.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.18 | 52 Week High | $1.45 | |||
| Open | $11.16 | 52 Week Low | $0.50 | |||
| Day High | $11.78 | P/E | N/A | |||
| Day Low | $10.86 | EPS | $0.00 | |||
| Volume | 304,884 | |||||
